### **Funding Levels/Project Periods**

The administrative and funding instrument to be used for the NCDRRC will be a cooperative agreement, in which substantial MCHB scientific and/ or programmatic involvement with the awardee is anticipated during the performance of the project. Under the terms of this cooperative agreement, in addition to the required monitoring and technical assistance, Federal responsibilities will include:

(1) Participation in meetings conducted during the period of the cooperative agreement.

(2) Ongoing review of activities and procedures to be established and implemented.

(3) Review of project information prior to dissemination.

(4) Review of information on project activities.

(5) Assistance with the establishment of contacts with Federal and State agencies, MCHB grant projects, and other contacts that may be relevant to the project's mission; and referrals to these agencies.

One project will be approved for three years. Up to \$300,000 in fiscal year 2002 funds will be used to fund the first year. Additional funding of up to \$300,000 annually in years two and three will be contingent on the availability of funds, and grantee performance.

# **Review** Criteria

Applications that are complete and responsive to the guidance will be evaluated by an objective review panel specifically convened for this solicitation and in accordance with HRSA grants management policies and procedures.

Applications will be reviewed using the following criteria:

# 1. Knowledge and Understanding of the Issues relating to CDR (Weight: 20%)

• The degree of understanding of the beginnings of CDR and the evolution of the CDR process as a public health model

• The degree of thoroughness in describing the CDR process and the challenges involved in creating and sustaining it in States and localities

• The extent of applicant knowledge of community-based systems in child and adolescent health and safety

• The extent of applicant knowledge of the individuals and organizations involved in the CDR process and the relationship of CDR and FIMR

## 2. Soundness and Adequacy of Project Plan (Weight: 30%)

• The extent to which the project objectives address the program purpose

and are measurable, time-framed, and appropriate in relation to both the program requirements and identified needs.

• The degree to which the program areas outlined in the grant guidance have been addressed, prioritized and justified.

• The quality and feasibility of the project plan or methodology and its relation to the project's goals and objectives.

• The extent to which the proposed approach identifies the resources that will be used to implement the strategies.

• The degree to which the approaches are technically sound and appropriate to the project goals and objectives.

3. Soundness of Evaluation Plan (Weight: 10%)

• The soundness of the plan for evaluating the process and outcome of this project.

• The extent to which the applicant describes how the project staff will determine the degree to which proposed activities are being successfully conducted and completed, based on the objectives outlined.

4. Applicant's Capability and Capacity (Weight: 30%)

• The extent to which the applicant has demonstrated expertise and its capability to oversee and successfully carry out the project.

• Evidence that a sufficient number of project personnel and resources are proposed. Biographical sketches/ curricula vitae document education, skills and experience that are relevant and necessary for the proposed project.

5. Appropriateness of Budget (Weight: 10%)

• The extent to which the proposed budget is realistic, adequately justified, and consistent with the proposed project plan.

• The extent to which the costs of administration and monitoring/ evaluation are reasonable and proportionate to the costs of service provision.

• The degree to which the costs of the proposed project are economical in relational to the proposed service utilization.

Additional criteria may be used to review and rank applications for this competition. Any such criteria will be identified in the program guidance included in the application kit. Applicants should pay strict attention to addressing these criteria, in addition to those referenced above. Also, to the extent that regulatory review criteria generally applicable to all Title V programs (at 42 CFR 51a) are relevant to this specific project, such factors will be taken into account.

# **Paperwork Reduction Act**

OMB approval for any data collection in connection with this cooperative agreement will be sought, as required under the Paperwork Reduction Act of 1995.

#### **Executive Order 12372**

The MCH Federal Set-Aside program has been determined to be a program which is not subject to the provisions of Executive Order 12372 concerning intergovernmental review of Federal programs.

Dated: May 16, 2002.

# Elizabeth M. Duke,

Administrator.

[FR Doc. 02–14681 Filed 6–11–02; 8:45 am] BILLING CODE 4165–15–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Host-Tumor Cell Interactions in Myeloma: Therapeutic Applications.

Date: July 1–3, 2002.

*Time:* 7 p.m. to 11 a.m.

*Agenda*: To review and evaluate grant applications.

*Place:* The Inn at Longwood Medical, 342 Longwood Avenue, Boston, MA 02115.

*Contact Person:* William D. Merritt, PhD, Scientific Review Administrator, Grants Review Branch, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8034, MSC 8328, Bethesda, MD 20892–8328, 301–496–9767.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: June 6, 2002.

#### LaVerne Y. Stringfield.

Director. Office of Federal Advisory Committee Policy. [FR Doc. 02-14804 Filed 6-11-02; 8:45 am] BILLING CODE 4140-01-M

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

# National Cancer Institute; Notice of **Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name Committee: National Cancer Institute Special Emphasis Panel PAR-02-052 Competing Supplements for Organotypic Models of Cancer.

Date: June 21, 2002.

*Time:* 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: 6130 Executive Boulevard, EPN, Conference Room J, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: C Michael Kerwin, PhD, Scientific Review Administrator, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8057, Msc 8329, Bethesda, MD 20892-8329, 301-496-7412, kerwinm@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.392, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health, HHS)

Dated: June 6, 2002.

# LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy. [FR Doc. 02-14805 Filed 6-11-02; 8:45 am] BILLING CODE 4140-01-M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# National Institutes of Health

# National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Cancer Epidemiology and Prevention Research.

Date: July 16-17, 2002.

*Time:* 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Mary Jane Slesinski, PhD, Scientific Review Administrator, Special Review and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8045, Bethesda, MD 20892, 301/594-1566.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93,396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: June 5, 2002.

#### LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-14809 Filed 6-11-02; 8:45 am] BILLING CODE 4140-01-M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Cancer Institute; Notice of **Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secretes or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Behavioral Research and Cancer Control.

Date: July 23, 2002.

*Time:* 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Mary Jane Slesinski, PhD, Scientific Review Administrator, Special Review and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8045, Bethesda, MD 20892, 301/594-1666.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393. Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: June 5, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-14810 Filed 6-11-02; 8:45 am] BILLING CODE 4140-01-M

# DEPARTMENT OF HEALTH AND **HUMAN SERVICES**

## **National Institutes of Health**

# National Cancer Institute; Notice of **Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice